CA2933065C - Materials and methods for controlling infections - Google Patents
Materials and methods for controlling infections Download PDFInfo
- Publication number
- CA2933065C CA2933065C CA2933065A CA2933065A CA2933065C CA 2933065 C CA2933065 C CA 2933065C CA 2933065 A CA2933065 A CA 2933065A CA 2933065 A CA2933065 A CA 2933065A CA 2933065 C CA2933065 C CA 2933065C
- Authority
- CA
- Canada
- Prior art keywords
- chlorhexidine
- solution
- site
- active agent
- disinfectant composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000015181 infectious disease Diseases 0.000 title abstract description 58
- 238000000034 method Methods 0.000 title abstract description 25
- 239000000463 material Substances 0.000 title abstract description 20
- 239000000243 solution Substances 0.000 claims description 61
- 238000001356 surgical procedure Methods 0.000 claims description 20
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 18
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000002324 minimally invasive surgery Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 abstract description 103
- 229960003260 chlorhexidine Drugs 0.000 abstract description 103
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 80
- 239000013543 active substance Substances 0.000 description 67
- 239000000645 desinfectant Substances 0.000 description 60
- 210000001519 tissue Anatomy 0.000 description 33
- 230000002262 irrigation Effects 0.000 description 24
- 238000003973 irrigation Methods 0.000 description 24
- 239000000644 isotonic solution Substances 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 18
- 239000007943 implant Substances 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 12
- 230000035876 healing Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 9
- 230000002939 deleterious effect Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 210000000653 nervous system Anatomy 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 201000003883 Cystic fibrosis Diseases 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010041925 Staphylococcal infections Diseases 0.000 description 4
- 208000002847 Surgical Wound Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000001467 acupuncture Methods 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007917 intracranial administration Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940059082 douche Drugs 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 208000031973 Conjunctivitis infective Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 241000222126 [Candida] glabrata Species 0.000 description 2
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000000613 ear canal Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 125000003345 AMP group Chemical group 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000144583 Candida dubliniensis Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 241001508813 Clavispora lusitaniae Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010010984 Corneal abrasion Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 206010049654 Spinal cord infection Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000501 collagen implant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000010433 feldspar Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 239000003061 homeopathic agent Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000003894 surgical glue Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915281P | 2013-12-12 | 2013-12-12 | |
| US61/915,281 | 2013-12-12 | ||
| PCT/US2014/070059 WO2015089421A1 (en) | 2013-12-12 | 2014-12-12 | Materials and methods for controlling infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2933065A1 CA2933065A1 (en) | 2015-06-18 |
| CA2933065C true CA2933065C (en) | 2021-08-24 |
Family
ID=53367098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2933065A Active CA2933065C (en) | 2013-12-12 | 2014-12-12 | Materials and methods for controlling infections |
Country Status (15)
| Country | Link |
|---|---|
| US (9) | US9642820B2 (OSRAM) |
| EP (1) | EP3079681B1 (OSRAM) |
| JP (2) | JP2017503852A (OSRAM) |
| KR (1) | KR20160096678A (OSRAM) |
| CN (1) | CN105979940A (OSRAM) |
| AU (2) | AU2014361828A1 (OSRAM) |
| BR (1) | BR112016013199A2 (OSRAM) |
| CA (1) | CA2933065C (OSRAM) |
| CL (1) | CL2016001447A1 (OSRAM) |
| IL (1) | IL246087A0 (OSRAM) |
| MX (1) | MX388424B (OSRAM) |
| PH (1) | PH12016501099A1 (OSRAM) |
| RU (1) | RU2682642C1 (OSRAM) |
| SG (2) | SG10201811454WA (OSRAM) |
| WO (1) | WO2015089421A1 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
| GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
| GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
| DK2648795T3 (da) | 2010-12-08 | 2023-03-27 | Convatec Technologies Inc | System til fjernelse af eksudater fra en sårposition |
| CN103347562B (zh) | 2010-12-08 | 2016-08-10 | 康沃特克科技公司 | 伤口分泌液系统附件 |
| CA2819475C (en) | 2010-12-08 | 2019-02-12 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
| GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
| GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
| GB201120693D0 (en) | 2011-12-01 | 2012-01-11 | Convatec Technologies Inc | Wound dressing for use in vacuum therapy |
| MX2015007771A (es) | 2012-12-20 | 2015-09-04 | Convatec Technologies Inc | Procesamiento de fibras celulosicas quimicamente modificadas. |
| CN105979940A (zh) | 2013-12-12 | 2016-09-28 | 创新技术股份有限公司 | 控制感染的材料和方法 |
| US10016375B2 (en) | 2013-12-12 | 2018-07-10 | Paul J. Rucinski | Materials and methods for controlling infections |
| US9848604B2 (en) * | 2014-07-11 | 2017-12-26 | Medtronic Xomed, Inc. | Antimicrobial wash |
| EP3177333A4 (en) * | 2014-08-08 | 2018-04-04 | Innovation Technologies, Inc. | Materials and methods for controlling infections with negative pressure wound therapy |
| GB2543544A (en) | 2015-10-21 | 2017-04-26 | Brightwake Ltd | Wound dressing |
| JP7183146B2 (ja) | 2016-03-30 | 2022-12-05 | コンバテック・テクノロジーズ・インコーポレイテッド | 創傷における微生物感染の検出 |
| JP2019513238A (ja) | 2016-03-30 | 2019-05-23 | クオリザイム・ダイアグノスティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＱｕａｌｉｚｙｍｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｇｍｂｈ Ａｎｄ Ｃｏ． Ｋｇ | 創傷における微生物感染の検出 |
| CA3022983C (en) * | 2016-05-06 | 2024-05-07 | SaCSh Corp. | Ophthalmic compositions comprising chlorhexidine and an anti-inflammatory agent |
| GB201608099D0 (en) | 2016-05-09 | 2016-06-22 | Convatec Technologies Inc | Negative pressure wound dressing |
| DK3481360T3 (da) | 2016-07-08 | 2022-03-28 | Convatec Technologies Inc | Fluidstrømningsmåling |
| KR20190026858A (ko) | 2016-07-08 | 2019-03-13 | 컨바텍 테크놀러지스 인크 | 가요성 부압 시스템 |
| BR112019000284A2 (pt) | 2016-07-08 | 2019-04-16 | Convatec Technologies Inc. | aparelho de coleta de fluido |
| EP3532043A4 (en) * | 2016-10-26 | 2020-09-09 | Innovation Technologies, Inc. | MATERIALS AND METHODS OF CONTROLLING A BIOFILM |
| CA3073325A1 (en) * | 2017-08-25 | 2019-02-28 | AZ Solutions LLC | System and method for wound treatment and irrigation |
| US11045589B2 (en) | 2017-09-22 | 2021-06-29 | Becton, Dickinson And Company | 4% trisodium citrate solution for use as a catheter lock solution |
| US20190117569A1 (en) * | 2017-10-24 | 2019-04-25 | Saint Anthony Biomedical, LLC | Compositions and methods for reducing infection in wounds and surgical sites |
| EP3710074B1 (en) | 2017-11-16 | 2024-03-20 | ConvaTec Limited | Fluid collection apparatus |
| WO2020005785A1 (en) * | 2018-06-26 | 2020-01-02 | Innovation Technologies, Inc. | Pyrogen binding composition and use of same in treatment and prevention of sepsis |
| EP3962544B1 (en) | 2019-06-03 | 2023-11-08 | Convatec Limited | Methods and devices to disrupt and contain pathogens |
| US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
| US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
| CN112294789B (zh) * | 2020-10-15 | 2022-06-07 | 郑涛 | 用于防治呼吸道感染的复方制剂及其应用 |
| EP4247352A1 (en) * | 2020-11-18 | 2023-09-27 | Institut Curie | Dimers of biguanidines and their therapeutic uses |
| US11722993B2 (en) * | 2021-03-23 | 2023-08-08 | Qualcomm Incorporated | Techniques for configuring resources in a sidelink resource pool |
| US11951087B2 (en) | 2021-07-27 | 2024-04-09 | Lanny Leo Johnson | Eye wash compositions and methods |
| US20250282811A1 (en) * | 2021-10-02 | 2025-09-11 | Desert King Chile S.A | A 3-o-monodesmosidic saponins extract, stable at physiological ph, method for preparing it from a quillaja plant extract cultured with a microbial consortium, uses and such microbial consortium |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2090354A (en) * | 1936-05-14 | 1937-08-17 | Abraham E Massman | Combined medicine dropper and swab |
| US4299221A (en) * | 1979-09-28 | 1981-11-10 | Stryker Corporation | Irrigation and suction handpiece |
| US4704102A (en) * | 1982-09-30 | 1987-11-03 | Geneco Inc. | Method of eliminating intra abdominal infections |
| US5002769A (en) * | 1987-03-13 | 1991-03-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for the sustained-release of chlorhexidine |
| IE883722L (en) * | 1988-12-14 | 1990-06-14 | Galway Dental Technology Ltd | Fluid dispenser for the treatment of a dental disorder |
| US4925668A (en) * | 1989-01-18 | 1990-05-15 | Becton, Dickinson And Company | Anti-infective and lubricious medical articles and method for their preparation |
| US5002528A (en) * | 1989-12-15 | 1991-03-26 | Aubrey Palestrant | Percutaneous irrigation and drainage system |
| US5333603A (en) * | 1992-02-25 | 1994-08-02 | Daniel Schuman | Endoscope with palm rest |
| US6558686B1 (en) | 1995-11-08 | 2003-05-06 | Baylor College Of Medicine | Method of coating medical devices with a combination of antiseptics and antiseptic coating therefor |
| JPH09301858A (ja) * | 1996-05-13 | 1997-11-25 | Senju Pharmaceut Co Ltd | グルコン酸クロルヘキシジン安定化水性薬剤 |
| US5725311A (en) | 1996-07-19 | 1998-03-10 | Sage Products, Inc. | Resealable package with label peeling inhibiting means |
| JP3054758B2 (ja) * | 1997-03-27 | 2000-06-19 | 小林製薬株式会社 | 外傷用組成物 |
| US5906278A (en) | 1997-10-06 | 1999-05-25 | Sage Products, Inc. | Patient bathing system |
| US5956794A (en) | 1997-10-31 | 1999-09-28 | Sage Products, Inc. | Patient bathing system and washcloth for body cleansing |
| RU2166314C2 (ru) * | 1999-07-06 | 2001-05-10 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Лечебно-профилактическое средство "гексикон", обладающее антибактериальным и антисептическим действием |
| US7066932B1 (en) * | 2001-05-26 | 2006-06-27 | Map Technologies Llc | Biologically enhanced irrigants |
| US6964653B2 (en) * | 2002-02-06 | 2005-11-15 | Felipe Negron | Multi-use hygienic cleansing device |
| US7066916B2 (en) | 2003-05-12 | 2006-06-27 | Sage Products, Inc. | Disinfectant delivery system, and method of providing alcohol-free disinfection |
| RU2240821C1 (ru) * | 2003-06-02 | 2004-11-27 | Научно-исследовательский институт вакцин и сывороток им. И.И.Мечникова РАМН | Способ лечения урогенитальных инфекций |
| IL156945A0 (en) * | 2003-07-15 | 2004-02-08 | Itzhak Tavori | Device and a method for orthopedic delivery of bone reconstruction medium |
| KR101158954B1 (ko) | 2003-09-22 | 2012-06-21 | 이노베이션 테크놀로지스, 인코포레이티드 | 상처 세척 장치 및 방법 |
| US20050191247A1 (en) | 2004-03-01 | 2005-09-01 | David Drake | Chlorhexidine compositions |
| WO2007003028A1 (en) * | 2005-07-01 | 2007-01-11 | Kane Biotech Inc. | Antimicrobial compositions for inhibiting growth and proliferation of a microbial biofilm on medical devices |
| US20080139450A1 (en) * | 2005-07-01 | 2008-06-12 | Srinivasa Madhyastha | Antimicrobial Compositions and Uses Thereof |
| WO2008060380A2 (en) * | 2006-10-18 | 2008-05-22 | Arrow International, Inc. | Anti-infective alcohol catheter solution with chlorhexidine treated catheter |
| US20110097372A1 (en) * | 2009-10-26 | 2011-04-28 | Rucinski Paul J | Devices, methods, and compositions for controlling infections |
| WO2013033159A1 (en) * | 2011-08-31 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | Reduction of biofilms on medical devices |
| GB0716605D0 (en) | 2007-08-24 | 2007-10-03 | Univ Aston | Skin antiseptics |
| US8696820B2 (en) * | 2008-03-31 | 2014-04-15 | Bard Access Systems, Inc. | Method of removing a biofilm from a surface |
| CN102056600A (zh) * | 2008-04-07 | 2011-05-11 | 界面生物公司 | 用于治疗细菌感染的组合疗法 |
| WO2010014676A1 (en) * | 2008-08-01 | 2010-02-04 | Ondine International Ltd. | Composition and method for treatment of mrsa |
| US8622996B2 (en) * | 2008-10-27 | 2014-01-07 | Pursuit Vascular, Inc. | Method for applying antimicrobial to proximal end of catheter |
| RU2455037C2 (ru) * | 2009-05-14 | 2012-07-10 | Государственное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ локальной иммунокоррекции инфекционно-воспалительных заболеваний урогенитального тракта женщин, вызванных микроорганизмами, передаваемыми половым путём |
| JP5639345B2 (ja) * | 2009-05-27 | 2014-12-10 | 花王株式会社 | バイオフィルム除去剤組成物 |
| RU2404430C1 (ru) * | 2009-07-27 | 2010-11-20 | Ирина Дмитриевна Евтушенко | Способ диагностики атрофии влагалища у женщин репродуктивного возраста в состоянии постовариоэктомии |
| EP2493442A4 (en) * | 2009-10-26 | 2013-05-15 | Innovation Technologies Inc | DEVICES, METHODS AND COMPOSITION FOR COMBATING INFECTIONS |
| US8343525B2 (en) | 2009-12-22 | 2013-01-01 | Becton, Dickinson And Company | Chlorhexidine acetate antiseptic cleaning agent |
| JP2013532716A (ja) * | 2010-08-05 | 2013-08-19 | ヘルパービー セラピューティクス リミテッド | ピロロキノリン化合物と、β−ラクタム系抗微生物剤、ムピロシンまたはクロルヘキシジンとの組み合わせ |
| US8529546B2 (en) * | 2010-10-21 | 2013-09-10 | John J. Martinez | Sinusal guide cannula and kit for irrigation, suction and washing |
| US20120150131A1 (en) | 2010-12-09 | 2012-06-14 | Teleflex Medical Incorporated | Polymer for Controlling Delivery of Bioactive Agents and Method of Use |
| US9327095B2 (en) * | 2013-03-11 | 2016-05-03 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
| CN103211805A (zh) * | 2013-04-18 | 2013-07-24 | 江苏健裕健康医疗器械有限公司 | 洗必泰葡萄糖酸盐复合消毒液 |
| US9345414B1 (en) | 2013-09-25 | 2016-05-24 | Bardy Diagnostics, Inc. | Method for providing dynamic gain over electrocardiographic data with the aid of a digital computer |
| CN105979940A (zh) | 2013-12-12 | 2016-09-28 | 创新技术股份有限公司 | 控制感染的材料和方法 |
-
2014
- 2014-12-12 CN CN201480075338.1A patent/CN105979940A/zh active Pending
- 2014-12-12 US US14/568,925 patent/US9642820B2/en active Active
- 2014-12-12 JP JP2016558541A patent/JP2017503852A/ja active Pending
- 2014-12-12 KR KR1020167018379A patent/KR20160096678A/ko not_active Ceased
- 2014-12-12 EP EP14869131.4A patent/EP3079681B1/en not_active Not-in-force
- 2014-12-12 MX MX2016007679A patent/MX388424B/es unknown
- 2014-12-12 RU RU2016127804A patent/RU2682642C1/ru active
- 2014-12-12 AU AU2014361828A patent/AU2014361828A1/en not_active Abandoned
- 2014-12-12 CA CA2933065A patent/CA2933065C/en active Active
- 2014-12-12 WO PCT/US2014/070059 patent/WO2015089421A1/en not_active Ceased
- 2014-12-12 BR BR112016013199-1A patent/BR112016013199A2/pt not_active Application Discontinuation
- 2014-12-12 SG SG10201811454WA patent/SG10201811454WA/en unknown
- 2014-12-12 SG SG11201604596RA patent/SG11201604596RA/en unknown
-
2016
- 2016-05-30 US US15/168,176 patent/US9668989B2/en active Active
- 2016-06-03 US US15/173,089 patent/US9931310B2/en active Active
- 2016-06-07 IL IL246087A patent/IL246087A0/en unknown
- 2016-06-09 PH PH12016501099A patent/PH12016501099A1/en unknown
- 2016-06-10 CL CL2016001447A patent/CL2016001447A1/es unknown
-
2017
- 2017-11-03 US US15/803,255 patent/US10172813B2/en active Active
- 2017-11-03 US US15/803,279 patent/US10226437B2/en active Active
-
2018
- 2018-03-31 US US15/942,471 patent/US10507191B2/en active Active
- 2018-11-29 AU AU2018271354A patent/AU2018271354B2/en active Active
-
2019
- 2019-05-24 JP JP2019097364A patent/JP2019189613A/ja active Pending
- 2019-06-22 US US16/449,361 patent/US10682318B2/en active Active
-
2020
- 2020-05-30 US US16/888,678 patent/US11033517B2/en active Active
-
2021
- 2021-05-08 US US17/315,294 patent/US11559503B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11559503B2 (en) | Materials and methods for controlling infections | |
| CA2669958C (en) | Devices and methods for delivering active agents to target sites | |
| US20210154158A1 (en) | Devices, methods, and compositions for controlling infections | |
| KR20220027799A (ko) | 항미생물제 내성의 유도 없이 생물막을 치료하기 위한 조성물 | |
| CN113747873A (zh) | 用于处理瞬时生物膜的组合物和方法 | |
| US10016375B2 (en) | Materials and methods for controlling infections | |
| CA2778081A1 (en) | Devices, methods, and composition for controlling infections | |
| HK1227710A1 (en) | Materials and methods for controlling infections | |
| KR20220033730A (ko) | 차아염소산 및 아세트산을 포함하는 항균 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191009 |